Inovio is "Addressing multi-billion-dollar market opportunities."
Cervical dysplasia/cancer caused by human papillomavirus (HPV) - VGX -3100 (Inovio owned) - Enrolling international phase II study; expect results 1Q 2014
HIV - PENNVAX-B - Phase I - Final HIV-001 results expected in 1H 2013
HIV - PENNVAX-G - Phase I - Initiate phase I clinical trial 1H 2013
HIV - PENNVAX-GP - Initiate phase I clinical trial 1H 2013
Hepatitis C - INO 8000 (Inovio owned) - Phase I/IIa clinical trial in HCV infected individuals (2H 2013)
Pandemic Flu -H5N1 Preventative - VGX-3400X (Inovio owned) - Report data from phase I study (1H 2013)
Seasonal Flu (H5N1 + H1N1)- Report interim phase I clinical data (1H 2013)
Seasonal Flu (H1N1, elderly) - Report interim phase I clinical data (2013)
Prostate Cancer - INO-5150 SynCon (Inovio owned) - Initiate phase I clinical trial (2013)
Leukemia - Phase II - Additional data (2013)
Hepatitis C - Chronvac C - Interim results of phase II (1Q 2013)
Additional Vaccines in the Pipeline:
Malaria, Foot & Mouth Disease , Chikungunya virus, dengue fever and "and other tropical infectious diseases, some which pose potential risk for bioterrorism use."
Sentiment: Strong Buy
Meet the Biotech CEO With a $30 Billion Breakthrough
By Michael A. Robinson, Defense and Technology Specialist, Money Morning
January 17, 2013
Don't worry if you never heard of Dr. J. Joseph Kim. Most investors haven't-at least not yet.
He's the CEO of an early-stage biotech firm that has developed a truly novel product for one of the nation's major medical markets -- vaccines.
It's a $30 billion a year business in just the U.S. alone.
The problem is that the vaccine technology we use today to prevent diseases like the flu, chicken pox and polio is hopelessly outdated because it still relies on the delivery of a portion of the actual virus to develop immunity.
Not only that, but some of these agents are still grown in chicken eggs like they were back in the 1930s.
And while they are still relatively safe, the vaccines themselves or their additives can still make people sick.
But what if you could develop a whole new class of vaccines that were actually safe using a synthetic DNA?
Better yet, what if you could vaccinate yourself against HIV, cervical cancer, leukemia, and hepatitis?
The payoff would be tremendous.
The Promise of Synthetic Vaccines
As luck would have it, my timing couldn't have been better.
On the day we met over dinner, Inovio's stock jumped some 17% on the announcement that it had received major backing from an anti-malaria foundation formed by none other than Bill and Melinda Gates.
And it wasn't the first time a group tied to one of the world's richest men -- and himself an expert in "disruptive" technology -- has backed Kim's approach.
In fact, the Gates-led PATH Malaria Vaccine Initiative has invested millions in Kim's company.
But that wasn't the only event related to our meeting at a posh San Francisco restaurant that sits hard by the historic Bay Bridge.
Just that very day headline after headline focused on the growing flu epidemic that has sickened thousands around the U.S.
Since Inovio is working on a "universal" flu vaccine made from synthetic DNA, Kim was the perfect person to talk with about this emerging new field.
Sentiment: Strong Buy